RATIONALE: Nicotinic acetylcholine receptors (nAChRs) have been implicated in the pathophysiology of cognitive deficits in the domains of attention and memory in schizophrenia. While nicotinic agonists and antagonists have been proposed as smoking cessation aids, few comparisons have been made of these agents on cognitive performance in individuals with schizophrenia. OBJECTIVES: This study investigated the acute effects of a nAChR antagonist, mecamylamine, and partial agonist, varenicline, on cognitive function in non-smokers with and without schizophrenia. METHODS: Single oral doses of mecamylamine 10 mg, varenicline 1 mg, and placebo were administered 1 week apart in random order to adults with schizophrenia (n = 30) and to healthy volunteers (n = 41) in a double-blind, crossover design. The primary outcome of interest was sustained attention as assessed with hit reaction time variability (HRT-SD) on the identical pairs continuous performance test (CPT-IP). RESULTS:Mecamylamine worsened performance on CPT-IP HRT-SD, a measure of attention, compared to varenicline in both groups. Performance on mecamylamine was worse than performance on both placebo and varenicline on several additional measures of attention, including CPT-IP hit reaction time (HRT) and random errors at various levels of task difficulty. There was a treatment by diagnosis interaction, such that mecamylamine worsened performance on CPT-IP 2-digit HRT, 3-digit random errors, and 4-digit hit rate compared to placebo and varenicline in participants with schizophrenia; effects not observed in controls. CONCLUSIONS: These findings support a role for nAChRs in attention and suggest that those with schizophrenia may be particularly sensitive to nAChR blockade.
RCT Entities:
RATIONALE: Nicotinic acetylcholine receptors (nAChRs) have been implicated in the pathophysiology of cognitive deficits in the domains of attention and memory in schizophrenia. While nicotinic agonists and antagonists have been proposed as smoking cessation aids, few comparisons have been made of these agents on cognitive performance in individuals with schizophrenia. OBJECTIVES: This study investigated the acute effects of a nAChR antagonist, mecamylamine, and partial agonist, varenicline, on cognitive function in non-smokers with and without schizophrenia. METHODS: Single oral doses of mecamylamine 10 mg, varenicline 1 mg, and placebo were administered 1 week apart in random order to adults with schizophrenia (n = 30) and to healthy volunteers (n = 41) in a double-blind, crossover design. The primary outcome of interest was sustained attention as assessed with hit reaction time variability (HRT-SD) on the identical pairs continuous performance test (CPT-IP). RESULTS:Mecamylamine worsened performance on CPT-IP HRT-SD, a measure of attention, compared to varenicline in both groups. Performance on mecamylamine was worse than performance on both placebo and varenicline on several additional measures of attention, including CPT-IP hit reaction time (HRT) and random errors at various levels of task difficulty. There was a treatment by diagnosis interaction, such that mecamylamine worsened performance on CPT-IP 2-digit HRT, 3-digit random errors, and 4-digit hit rate compared to placebo and varenicline in participants with schizophrenia; effects not observed in controls. CONCLUSIONS: These findings support a role for nAChRs in attention and suggest that those with schizophrenia may be particularly sensitive to nAChR blockade.
Authors: James Loughead; Riju Ray; E Paul Wileyto; Kosha Ruparel; Paul Sanborn; Steven Siegel; Ruben C Gur; Caryn Lerman Journal: Biol Psychiatry Date: 2010-03-06 Impact factor: 13.382
Authors: Jason Smucny; Korey P Wylie; Eugene Kronberg; Kristina T Legget; Jason R Tregellas Journal: J Psychiatr Res Date: 2017-02-03 Impact factor: 4.791
Authors: Alan S Lewis; Gerrit I van Schalkwyk; Michael H Bloch Journal: Prog Neuropsychopharmacol Biol Psychiatry Date: 2017-01-05 Impact factor: 5.067
Authors: Randi M Schuster; Corinne Cather; Gladys N Pachas; Haiyue Zhang; Kristina M Cieslak; Susanne S Hoeppner; David Schoenfeld; A Eden Evins Journal: Addict Behav Date: 2017-02-24 Impact factor: 3.913
Authors: Sarah A Berg; Alena M Sentir; Richard L Bell; Eric A Engleman; R Andrew Chambers Journal: Psychopharmacology (Berl) Date: 2014-11-13 Impact factor: 4.530
Authors: Randi Melissa Schuster; Gladys N Pachas; Luke Stoeckel; Corinne Cather; Mireya Nadal; David Mischoulon; David A Schoenfeld; Haiyue Zhang; Christine Ulysse; Elisabeth B Dodds; Sara Sobolewski; Vicenta Hudziak; Ailish Hanly; Maurizio Fava; A Eden Evins Journal: J Clin Psychopharmacol Date: 2018-08 Impact factor: 3.153
Authors: A Eden Evins; Susanne S Hoeppner; David A Schoenfeld; Bettina B Hoeppner; Corinne Cather; Gladys N Pachas; Kristina M Cieslak; Melissa Culhane Maravic Journal: Schizophr Res Date: 2016-12-09 Impact factor: 4.939
Authors: Robert C Smith; Revital Amiaz; Tian-Mei Si; Lawrence Maayan; Hua Jin; Sylvia Boules; Henry Sershen; Chunbo Li; Juanjuan Ren; Yanhong Liu; Mary Youseff; Abel Lajtha; Alessandro Guidotti; Mark Weiser; John M Davis Journal: PLoS One Date: 2016-01-05 Impact factor: 3.240